Effective January 16, 2014, Stemline Therapeutics, Inc. appointed David Gionco as Vice President of Finance and Chief Accounting Officer of the company and entered into an agreement governing the terms of Gionco's employment. This employment agreement became effective on January 16, 2014. Most recently Gionco was the Group Vice President, Chief Financial Officer and Chief Accounting Officer of Savient Pharmaceuticals, Inc. Prior to this Gionco held audit, corporate accounting, financial planning, finance and controller roles at companies including Merck & Co., Inc.